The ERA-EDTA will consider abstracts related to unpublished clinical trials for a special “Late breaking clinical trials” session. The following trials will be considered for evaluation if they comply with the required characteristics:

– a prospective randomised intervention in renal patients (medication, education, dietetics, physiotherapy, etc…), including at least 100 patients;

– a prospective observational study, including at least 500 patients;

– approved by an institutional ethical committee;

– not previously reported or published.

Abstracts may be accepted as oral communications or posters, after being evaluated by the review committee.

Abstracts that do not meet the criteria above will not be considered for presentation.

The LBCT abstract submission deadline expired on March 26, 2021.

The abstract submission deadline expired on January 15, 2021.

NEW IN 2021!

  • New abstract category: Sustainable Kidney Care
  • 50% discount on registration fee for the presenting authors of accepted abstracts
  • 15% discount on registration fee for the main authors of rejected abstracts


You can submit your abstracts from November 16, 2020.
The abstract submission expired on January 15, 2021 after 23:59 CET.

In order to begin the abstract submission you need to enter your My-ERA-EDTA account by using your credentials (for ERA-EDTA members and returning users). If you are a first time user, you need to create your own account.

Communications should concern all aspects of nephrology, the prevention and treatment of renal diseases and associated conditions and/or the scientific background to the study of the kidney.

Only submission through the congress website is possible. Abstracts sent by post or e-mail will not be accepted.

Your abstract file must be compliant to the following:

  • Use the template provided under the Upload tab. To be sure the format is correct, copy and paste your content without formatting (even if our system recognizes many fonts) into the file and save it with a new name.
  • Images inside the file should be in-lined (not below or above the text) and should not be too big (max 150dpi).
  • Keep text within the max characters (3400, spaces NOT included). The template headings are part of the counting and cannot be deleted. Whereas the title, author name, affiliation, and figures/images are not counted.

All authors of correctly written and successfully submitted abstracts will receive confirmation by e-mail. Should you experience any unforeseen problems with the electronic submission, please contact the ERA-EDTA Operative Headquarters at abstracts@era-edta.org.


You will automatically receive an e-mail confirming our receipt of your abstract.


The Presenting Author of each accepted abstract will be notified by March 24, 2021. If the Presenting Author is unable to present the abstract, another co-author can take his/ her place. However, if this is the case, a letter from the Presenting Author about the change is requested and it must be received by the ERA-EDTA Operative Headquarters no later than April 20, 2021.


Submitted abstracts cannot be withdrawn or changed. No exceptions will be made.


The presenting author must confirm that all co-authors agree with the submission and content of the abstract.

ERA-EDTA cannot be deemed responsible for any infringement of this rule.


All authors of abstracts grant the ERA-EDTA for an indefinite period of time, without territorial limitations and without any right to compensation, the right to make the abstract available to the public as well as to all other users, through the ERA-EDTA website and any other websites operated by the ERA-EDTA as well as via social media or any other website related to medical issues.

For more information, please check here the ERA-EDTA Terms and Conditions https://www.era-online.org/en/terms-and-conditions.


Submitted abstracts must describe unpublished work that is not already in press or awaiting possible acceptance by any other society that publishes its abstracts/proceedings.


All abstracts must be written in English.


All abstract submitters will have to fill in a simplified Disclosure of Interest (DOI) during the submission procedure. If after the review the abstract will be accepted at the Congress, they will be asked to fill in the complete DOI form when submitting their presentation.


A non-refundable processing fee of EUR 25.00 must be paid for each abstract submitted. The processing fee must be paid at the time of submission by credit card only. Major credit cards (MasterCard and Visa) are accepted for the secure online payment. All payments must be received by Friday, January 15, 2021 at 23.59 CET so that the submission can be finalised successfully. This fee is non refundable even if the abstract is rejected.

Abstract processing fees are waived for submitters from countries with an official annual income (GDP – Gross Domestic Product per Capita) below USD 10,000 (source: World Bank). A list of eligible countries can be accessed here.


The highest scoring abstracts will be presented as free communications, combined in sessions with mini lectures from world renowned scientists.



Your accepted abstract will receive great visibility through the “Mini-Orals” (4 slides – 5 minutes), pre-recorded Power Point files (including Q&A) which will substitute our traditional posters starting 2021.


All abstracts accepted for presentation will appear in NDT as an official online supplement. No abstract book will be printed. Abstracts will appear exactly as submitted. Any abstract considered unsuitable for reproduction will not be published.


A special certificate which shows the percentile reached by the abstract(s) will be given, as an exclusive benefit, to the authors of accepted abstracts who present their works at the Congress.